Consumer Health: Liver cancer --  risk factors and prevention
October is Liver Cancer Awareness Month, which makes this a good time to learn more about risk factors for liver cancer and what you can do to prevent it. More than 41,000 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. this year, and nearly 30,000 people will die of these diseases, according to the American Cancer Society. Liver cancer is cancer that begins in the cells of your liver, which… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 12, 2023 Category: Databases & Libraries Source Type: news

Dad diagnosed with bile duct cancer shares first signs - one symptom occurred at work
Dad-of-two Andrew Clay was on holiday in Devon when he first experienced strange symptoms. (Source: Daily Express - Health)
Source: Daily Express - Health - October 4, 2023 Category: Consumer Health News Source Type: news

Antibody Treatment Could Fight Rare But Deadly Bile Duct Cancers
MONDAY, June 12, 2023 -- Patients with bile duct cancer might soon have an additional treatment available to them, thanks to a newly discovered tumor target. Some bile duct cancers are driven by a mutated HER2 gene, which has also been implicated in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 12, 2023 Category: General Medicine Source Type: news

Antibody Treatment Zanidatamab Could Fight Rare But Deadly Bile Duct Cancers
MONDAY, June 12, 2023 -- Patients with bile duct cancer might soon have an additional treatment available to them, thanks to a newly discovered tumor target. Some bile duct cancers are driven by a mutated HER2 gene, which has also been implicated... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 12, 2023 Category: General Medicine Source Type: news

Dad, 35, dies from rare cancer just SIX days after marrying mother of his two kids
Chris McGinnis, from Nottinghamshire, was diagnosed with metastasis cholangiocarcinoma, a rare form of bile duct cancer, in February. (Source: the Mail online | Health)
Source: the Mail online | Health - May 17, 2023 Category: Consumer Health News Source Type: news

John Refoua Dies: ‘Avatar’ Film Editor Was 58
John Djahanshah Refoua, a film editor that worked on Avatar and Avatar: The Way of Water, has died. He was 58. Refoua had been diagnosed with a rare bile cancer called cholangiocarcinoma, his wife Serena Refoua confirmed. “Dear friends, my brilliant, sweet, creative husband John Djahanshah Refoua…#johndjahanshahrefoua #avatar #wayofwater #refoua #serenarefoua #serena #jamescamerons #averysophia #magnificentseven2016 #equalizer (Source: Reuters: Health)
Source: Reuters: Health - May 17, 2023 Category: Consumer Health News Source Type: news

Patients Needed for New Mesothelioma Clinical Trial
A new investigational drug for mesothelioma can now begin human trials after it was granted fast-track designation by the U.S. Food and Drug Administration last week. The novel treatment, SnyKIR-110, is a T-cell therapy designed to treat patients with mesothelioma, cholangiocarcinoma (bile duct cancer) and ovarian cancer.  “We are thrilled to receive fast-track designation from the FDA,” said Dr. Bryan Kim, co-founder and CEO of Verismo Therapeutics. “This designation is an important milestone in our efforts to bring this potentially life-saving drug to patients who are in need of new treatment option...
Source: Asbestos and Mesothelioma News - April 19, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news

Liver Transplants for CRC Metastases: Coming Into Its Own? Liver Transplants for CRC Metastases: Coming Into Its Own?
Although still controversial, transplantation is gaining traction as a treatment option for patients with colorectal liver metastases and intrahepatic cholangiocarcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

More Data Needed for Neoadjuvant Tx for Bile Duct Cancer More Data Needed for Neoadjuvant Tx for Bile Duct Cancer
In a debate held recently on the use of neoadjuvant therapy for high-risk intrahepatic cholangiocarcinoma, both sides agreed that more research is needed.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 5, 2023 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Bile Duct Cancer: Awareness, Funding Needed to Fight This Silent Killer
MONDAY, March 20, 2023 -- Lawyer, entrepreneur and avid athlete Mark Clements participated in the 2005 St. George Marathon in Utah, but ongoing stomach pains made finishing the event a struggle.“He was having some stomach pain,”... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 20, 2023 Category: General Medicine Source Type: news

Mayo Clinic Q and A: What is cholangiocarcinoma and how is it treated?
DEAR MAYO CLINIC: My mother has been experiencing unusual and persistent fatigue, abdominal pain, and jaundice. After undergoing a CT scan, her doctor diagnosed her with cholangiocarcinoma. What is this type of cancer? And what treatment options are available? ANSWER: Cholangiocarcinoma is a rare cancer that develops from the bile ducts, which are slender tubes that carry the digestive fluid bile and connect the liver to the gallbladder and small intestine. The tumor can occur anywhere along… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 21, 2023 Category: Databases & Libraries Source Type: news

Gallbladder & Bile Duct Cancers: Rare, Silent and Deadly. Know the Signs
WEDNESDAY, Feb. 1, 2023 – Bile duct and gallbladder cancers develop in organs deep inside the body, making them difficult to detect. Knowing the signs of these rare cancers may help with earlier detection. Gallbladder cancer and bile duct cancer... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 1, 2023 Category: General Medicine Source Type: news

Consumer Health: Treating liver cancer
October is Liver Cancer Awareness Month, which makes this a good time to learn more about treating liver cancer. More than 41,000 new cases of primary liver cancer and intrahepatic bile duct cancer will be diagnosed in the U.S. this year, and more than 30,000 people will die of these diseases, according to the American Cancer Society. Liver cancer is cancer that begins in the cells of your liver, which is a football-sized organ in the upper right portion… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - October 27, 2022 Category: Databases & Libraries Source Type: news

Latest Mesothelioma T-Cell Clinical Trial Moves to Phase II
The most recent T-cell therapy aimed at mesothelioma cancer has advanced to phase II of the clinical trial process, with researchers exploring its effectiveness when combined with an already approved immunotherapy duet. Investigators are studying the synergistic effect of gavocabtagene autoleucel (gavo-cel) when used with the combination of Opdivo and Yervoy, which was approved by the U.S. Food and Drug Administration in 2020 to treat mesothelioma. Its earlier phase I results, when used alone, were impressive – 93% of patients experienced tumor regression – raising hopes for a much-needed advancement in mesotheli...
Source: Asbestos and Mesothelioma News - October 17, 2022 Category: Environmental Health Authors: Lynette Zilio Source Type: news

Orphan Drug Designation Given to New Mesothelioma CAR T-Cell Therapy
In early 2023, the world-class Hospital of the University of Pennsylvania will open a groundbreaking clinical trial for mesothelioma patients utilizing a next-generation immunotherapy with a novel delivery platform. The U.S. Food and Drug Administration cleared the path in September by granting orphan drug designation for SynKIR-110, a CAR T-cell therapy designed to target solid tumors expressing a specific protein typically found in mesothelioma cancer. By granting the orphan drug designation, the FDA can provide financial incentives such as tax credits for clinical trials and seven years of market exclusivity. It i...
Source: Asbestos and Mesothelioma News - October 5, 2022 Category: Environmental Health Authors: Fran Mannino Source Type: news